Brief: Sunshine Lake Pharma Says NMPA Accepts Clinical Trial Application For HEC-921 Injection
18/06/2026 16:59
BRIEF-Sunshine Lake Pharma Says NMPA Accepts Clinical Trial Application For HEC-921 Injection June 18 (Reuters) - Sunshine Lake Pharma Co Ltd 6887.HK:
NMPA ACCEPTS CLINICAL TRIAL APPLICATION FOR HEC-921 INJECTION ON JUNE 18, 2026
Further company coverage: 6887.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sunshine Lake Pharma
See all newsBrief: Sunshine Lake Pharma Says Insulin Degludec Injection, Others Obtain Marketing Approval
Brief: Sunshine Lake Pharma Expects HY Loss Attributable RMB590 Million
Brief: Sunshine Lake Pharma Says Zhang Yushuai Purchases 1.5 Million H Shares
Brief: Sunshine Lake Pharma Obtains Nmpa Approval For Insulin Degludec Injection
Brief: Sunshine Lake Pharma Says Controlling Shareholder To Increase Shareholding By Hk$300 Million-Hk$600 Million In Next Six Months